Clinical Trials Logo

Clinical Trial Summary

Intro-stent restenosis, bifurcation lesions and small vascular lesion with diameter <2.75mm is the indication of drug coated balloon. In the era of traditional coronary artery balloon dilatation, it is believed that muscle fiber of coronary artery great vessels is more abundant than that of small vessels, and elastic recoil and dissection are easier to appear upon dilatation, which will result in acute vascular occlusion and restenosis, so it is not recommended for great vessels to only receive PTCA therapy. But for patients with good angiography result without combination of serious dissections after predilation, the acute thrombosis seems to be a key factor for acute vascular occlusion. Traditional antiplatelet drug doesn't have a good effect, but the application of new-generation antiplatelet drug (clopidogrel, ticagrelor and tirofiban) has greatly reduced the occurrence rate of acute thrombosis. Therefore, under the guarantee of fully antiplatelet action of new-generation antiplatelet drug, for the patients with good angiography result without combination of serious dissections after predilation, Drug coated balloon seems to be an alternative of the stent. This research is to verify the safety and efficacy of Drug coated balloon in de novo coronary artery lesion with vascular diameter ≥2.75mm.


Clinical Trial Description

Stable or unstable angina patients who accept drug coated balloon dilatation therapy with diameter stenosis≥50%, reference diameter≥2.75mm will be enrolled. OCT examination should be carried out after radiography, predilation, Drug coated balloon dilatation and follow-up.

For target lesion, balloon should be used for predilation (the ratio of balloon diameter to vascular diameter being 0.8-1.0:1), and for good predilation effects, high pressure balloon, cutting balloon, dual-wire balloon and spines balloon can be adopted. OCT examination should be carry out after balloon satisfactory predilation. Satisfactory predilation radiography result is residual stenosis≤30%,TIMI 3 flow without major dissections (type C or higher) in NHLBI classification. OCT satisfactory result is residual stenosis≤30% without dissection, or with dissection but the dissection angle is ≤90°. Then carry out DCB balloon dilatation therapy. The ratio of balloon diameter to vascular diameter is 0.8-1.0:1, and both ends of DCB exceed the preprocessing area of lesion for 2-3mm, thus avoiding the occurrence of geographical mismatch. Dilation pressure is 8-10atm, lasting for at least 30s. Each DCB catheter can be used once only. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03691675
Study type Interventional
Source Second Hospital of Jilin University
Contact Bin Liu, Doctor
Phone 13500810268
Email liubin3333@vip.sina.com
Status Not yet recruiting
Phase N/A
Start date October 2018
Completion date April 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05101005 - Long-term Efficacy of Drug-coated Balloon Versus Drug-eluting Stent in Large de Novo Coronary Lesions N/A
Recruiting NCT06084000 - STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial N/A
Recruiting NCT03360279 - DCB for Dialysis Access Stent Graft Restenosis N/A
Completed NCT04234893 - Bingo Drug-Coated Balloon in Real World
Not yet recruiting NCT06265324 - Drug-coated Balloon Treatment in Coronary Lesions N/A
Active, not recruiting NCT04826705 - A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon
Completed NCT04984135 - DCB Angioplasty for Coronary Lesions: an OCT Analysis
Recruiting NCT05562089 - Prevail Drug Balloon Study N/A
Recruiting NCT04619277 - Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion
Active, not recruiting NCT04937803 - Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS) N/A
Not yet recruiting NCT04778969 - Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database